Discrimination of serum metabolomics profiles in infants with sepsis, based on liquid chromatography-mass

Li Wang1,2, Xinyi Cha2, Zhongxiao Zhang3

  • 1Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, Institute for Advanced Study, Tongji University School of Medicine, Shanghai, China.

BMC Infectious Diseases
|January 23, 2023
PubMed

Insights

Early diagnosis of infant sepsis is crucial. This study identified serum metabolites, including prolylhydroxyproline, as potential biomarkers for early sepsis detection in infants, improving diagnostic accuracy.

Area of Science:

  • Pediatric Infectious Diseases
  • Metabolomics
  • Biomarker Discovery

Background:

  • Sepsis in infants presents with insidious onset and rapid progression, leading to high mortality rates.
  • Sensitive and robust biomarkers are essential for early diagnosis of infant sepsis.

Purpose of the Study:

  • To identify serum metabolic profiles and potential biomarkers for early diagnosis of infant sepsis.
  • To investigate the association of differential metabolites with clinical parameters and inflammatory pathways.

Main Methods:

  • Serum samples from 30 infants with sepsis and 30 controls were analyzed using liquid chromatography-mass spectrometry-based metabolomics.
  • Multivariate statistical analysis and ROC curves were employed to identify differential metabolites and assess diagnostic value.
  • Pathway and network analyses were conducted to understand the biological roles of identified metabolites.

Main Results:

  • Six differential metabolites were identified, including phosphatidic acid, phosphatidyl ethanolamine, cytidine 5'-diphosphocholine, sphingomyelin, prolylhydroxyproline, and phosphorylcholine.
  • Prolylhydroxyproline demonstrated potential diagnostic value (AUC=0.832), with a combined model achieving AUC=0.859.
  • Differential metabolites were correlated with C-reactive protein (CRP) and procalcitonin (PCT) levels and linked to inflammatory and metabolic signaling pathways.

Conclusions:

  • Serum metabolite profiling can aid in the early diagnosis of infant sepsis.
  • Prolylhydroxyproline, phosphatidyl ethanolamine, and cytidine 5'-diphosphocholine are identified as potential biomarkers for infant sepsis.
  • The findings provide insights into the metabolic dysregulation and inflammatory pathways involved in infant sepsis.